Rusija dominiše

epikur37 wrote:

veber wrote:

epikur37 wrote:inači ljudi s plavim očima bolje podnose cugu

a mi svi u obitelji imamo plave oči, žena djeca i ja

znači predisponirani smo na alkohol :D

onda ipak nisi turčin.
možda iranac ili semit. oni su plavooki.

najprije etiopljani...

majmune, somalke imaju zelene oči.
abesinci su nigeri.

Ringo10 wrote:

epikur37 wrote:

Ringo10 wrote:Frajer putuje od ne znam odakle do Krima, klip od 24 i pol minuta

Koji Mordor ova Rusija. Užas i katastrofa. Propast, bijeda, mizerija

https://www.youtube.com/watch?time_continue=8&v=zbeWGiARLE4&feature=emb_logo

Bože sačuvaj!

Bio si ironičan...video je ok..lijepo se razvija Rusija, općenito nova Europa .

Pa stalno slušam sranja kako je Rusija gora od Zimbabvea i da je samo Moskva i Piter relativno uredni i to samo u strogom centru a da je sve izvan toga u rangu Haitija.

Pun mi kitomir toga. Planiram da odem u Rusiju za dvije godine, idem u Vladivostok pa transsibirom preko Bajkala do Moskve i Sankt Pitera, onda do Sočija pa vlakom za Krim preko onoga mosta i tamo ostanem nekih 7 dana.

Pa da se osobno uvjerim u sve.

A ako budemo živi i zdravi, vidjet ćemo Rusiju 2030te kad završe sve te silne projekte u koje investiraju velike novce.

Sad su i provincijski gradovi tipa Tule sriktani, barem u samom centu... a Moskva je među najuređnijima gradovima u Europi. Doslovno se ruši sva stambena arhitektura iz SSSR-a

MOSCOW, August 11. /TASS/. The world's first registered vaccine against the coronavirus infection which was developed in Russia was named Sputnik V, the official vaccine website launched on Tuesday said.
"In 1957, the successful launch of the first man-made satellite by the Soviet Union activated space research in the entire world. Thanks to this comparison, the vaccine received the name of Sputnik V," the website explains. It is noted that currently over 160 vaccines against the coronavirus are developed worldwide.


The web resource is created "to spread detailed and up-to-date information about the vaccine" and "to fight the disinformation campaign about the vaccine launched by several international news outlets," the statement said. Earlier on Tuesday, head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev stated that there are "coordinated and carefully planned information attacks on the Russian vaccine" in the world.

[size=26]RDIF sees strong global interest in the vaccine and plans to conduct Phase 3 clinical trials in different countries, including [b]Saudi Arabia, UAE, Brazil, India and Philippines[/b], and start mass production in other countries in partnership with local sovereign wealth funds, including [b]India, South Korea and Brazil, as well as, in Saudi Arabia, Turkey and Cuba.[/b][/size]
[size=26]The plan is to ramp up the vaccine production to 200 million doses by the end of 2020 including 30 million doses in Russia.[/size]
[size=26]At least 20 countries had expressed interest in obtaining the Sputnik V, including [b]UAE, Saudi Arabia, Indonesia, Philippines, Brazil, Mexico and India.[/b][/size]

[size=36]FORBIDDEN OP-ED: THE SPUTNIK VACCINE AS A LIFESAVING GLOBAL PARTNERSHIP[/size]

This opinion piece, which tells the story behind the creation of the Russian vaccine against COVID-19 and emphasizes the willingness of Russia to cooperate with the international community, has been rejected by all leading Western media. We therefore decided to publish it as is in order to share our views with an international audience and to lift the blockade imposed on positive information about the Russian COVID-19 vaccine. We give right to all media outlets to re-publish this op-ed if they find it useful to present their readers with the history and some facts about the first registered coronavirus vaccine in the world. We believe that this information is crucial for the international effort to fight the world’s biggest challenge and would like readers to decide for themselves why this op-ed has been rejected. We also launched the website www.sputnikvaccine.com to provide accurate and up-to-date information about the vaccine.    
Russia’s success in developing COVID-19 vaccine is rooted in history
The “Sputnik moment” has happened. The Russian vaccine “Sputnik V” has been launched becoming the world’s first registered COVID-19 vaccine and evoking memories of the 1957 shock launch of a Soviet satellite, which opened space to exploration by humans. This new era led not only to competition but also to many collaborative efforts, including the joint Apollo-Soyuz mission by the United States and the Soviet Union.
A COVID-19 vaccine is the world’s number one priority and many countries, organizations and companies claim they are close to developing one. By the end of this year some other countries may have their own vaccines. It is important that political barriers do not prevent the best available technologies from being used for the benefit of all people in the face of the most serious challenge humankind has faced in decades.
Unfortunately, instead of looking into the science behind the proven adenoviral vector-based vaccine platform Russia has developed, some international politicians and media chose to focus on politics and attempts to undermine the credibility of the Russian vaccine. We believe that such an approach is counter-productive and call for a political “ceasefire” on vaccines in the face of COVID-19 pandemic.
It is not broadly known worldwide that Russia has been one of the global leaders in vaccine research for centuries. Russian Empress Catherine the Great set an example in 1768 when she received the country’s first smallpox vaccination, 30 years before the first vaccination was done in the United States.
In 1892 Russian scientist Dmitri Ivanovsky observed an unusual effect while studying tobacco leaves infected with a mosaic disease. The leaves remained infectious even after the scientist filtered out the bacteria. Although it was still almost half a century before the first virus could be seen through a microscope, Ivanovsky’s research gave birth to a new science called virology.
Since Ivanovsky’s discovery, Russia has been one of the global leaders in virology and vaccine research, producing scores of talented scientists such as researcher Nikolay Gamaleya, who studied at the laboratory of French biologist Louis Pasteur in Paris and opened the world’s second vaccination station for rabies in Russia in 1886.
The Soviet Union continued to support research into viruses and vaccines. Everyone born after the Second World War received mandatory vaccinations against polio, tuberculosis and diphtheria. In a rare example of Cold War era cooperation, three leading Soviet virologists went to the United States in 1955 to offer testing opportunities in the Soviet Union for a U.S. vaccine against polio, a deadly disease which claimed millions of lives. If we were able to cooperate then, we can and must do it again now.
Decades of efforts by Russian and Soviet scientists led to the creation of an excellent research infrastructure, such as the National Center of Epidemiology and Microbiology named after Nikolai Gamaleya. This infrastructure ranges from one of the richest “virus libraries” in the world, created using a unique preservation technique, to experimental animal breeding centers. We are proud of this legacy, which allowed us to create the first approved COVID-19 vaccine in the world. We already received international requests for 1 bln doses of our vaccine and reached international agreements to produce 500 mln doses annually with the intention to ramp it up.
THE REAL SECRET 

Today, many Western media and politicians question the speed of the COVID-19 vaccine creation  in Russia, raising doubts about its efficacy and authenticity. The secret behind this speed is Russia’s expertise in vaccine research. Since the 1980s, the Gamaleya Center has led the effort to develop a technological platform using adenoviruses, found in human adenoids and normally transmitting the common cold, as “vectors” or vehicles, which can induce a genetic material from another virus into a cell. The gene from adenovirus, which causes the infection, is removed while a gene with the code of a protein from another virus is inserted. This inserted element is small, not a dangerous part of a virus and is safe for the body but still helps the immune system to react and produce antibodies, which protect us from the infection.  
The technological platform of adenovirus-based vectors makes it easier and faster to create new vaccines through modifying the initial carrier vector with genetic material from new emerging viruses. Such vaccines provoke a strong response from a human body in order to build immunity while the overall process of vector modification and pilot-scale manufacturing takes only a few months.
Human adenoviruses are considered some of the easiest to engineer in this way and therefore they have become very popular as vectors. Since the start of the COVID-19 pandemic all Russian researchers had to do was to extract a coding gene from the spike of the novel coronavirus and implant it into a familiar adenovirus vector for delivery into a human cell. They decided to use this already proven and available technology instead of going into uncharted territory.   
The most recent studies also indicate that two shots of the vaccine are needed to create a long-lasting immunity. Since 2015 Russian researchers have been working on a two-vector approach hence the idea to use two types of adenoviral vectors, Ad5 and Ad26, in the COVID-19 vaccine. In this way, they trick the body, which has developed immunity against the first type of vector, and boost the effect of the vaccine with the second shot using a different vector.   It is like two trains trying to deliver an important cargo to a fortress of a human body which needs the delivery in order to start producing antibodies. You need the second train to make sure the cargo reaches its destination. The second train should be different from the first one, which already came under attack from the body’s immune system and is already familiar to it. So, while other vaccine makers have only one train, we have two.
With its two-vector approach the Gamaleya Center also developed and registered a vaccine against Ebola fever. This vaccine has been used on several thousand people over the last few years creating a proven vaccine platform that was used for the COVID-19 vaccine. Аbout 2,000 people in Guinea received injections of Gamaleya vaccines in 2017-18 and the Gamaleya Center has an international patent for its Ebola vaccine.
TWO VECTOR APPROACH 

The Gamaleya Center used adenoviral vectors to develop vaccines against influenza and against Middle East Respiratory Syndrome (MERS). Both vaccines are currently in advanced stages of clinical trials. These achievements show that Russian labs did not waste their time in the last few decades while the international pharmaceutical industry often underestimated the importance of new vaccines research in the absence of global health threats prior to the COVID-19 pandemic. 
Other countries follow in our footsteps developing adenoviral vector-based vaccines.  Oxford University is using an adenovirus from a monkey, which has neither been used in an approved vaccine before unlike human adenoviruses. U.S. company Johnson & Johnson is using adenovirus Ad26 and China’s CanSino - adenovirus Ad5, the same vectors the Gamaleya Center is using, but they are yet to master the two-vector approach. Both companies already received large orders for vaccines from their governments.
The use of two vectors is the unique technology, developed by the Gamaleya Center scientists, which differentiates the Russian vaccine from other adenoviral vector-based vaccines under development around the world. Vaccines based on adenoviral vectors also have clear advantages over other technologies such as mRNA vaccines.
Prospective mRNA vaccines, undergoing clinical trials in the United States and other countries, do not use vectors for delivery and represent an RNA molecule with coronavirus protein code wrapped in a lipid membrane. This technology is promising but its side effects, especially an impact on fertility, have not yet been studied in depth. No mRNA vaccine has yet received regulatory approval in the world. We believe that in the global vaccine race to fight coronavirus adenoviral vector-based vaccines will be the winners but even in this category the Gamaleya vaccine has the edge.
CONFRONTING SKEPTICISM 

The Russian vaccine is now ready and registered. The first two phases of clinical trials are over and their results will be published this month in line with international requirements. These documents will provide detailed information about the vaccine, including the exact levels of antibodies as shown by several third-party tests as well as by Gamaleya’s proprietary test, which identifies the most efficient antibodies attacking the spike of coronavirus. They will also show that all the participants of the clinical trials developed a 100 percent immunity to COVID-19. Studies on Syrian hamsters, animals which usually die from COVID-19, showed 100% protection and an absence of lung-damage after they received a lethal infection dose. After the registration we will conduct international clinical trials in 3 other countries. Mass production of the vaccine is expected to start by September and we already see strong global interest in the vaccine.
Skepticism among international media and politicians has surfaced just as Russia announced its plans for mass COVID-19 vaccine production.  When I spoke with Western media many refused to include key facts about the Russian COVID-19 vaccine research in their stories. We view this skepticism as an attempt to undermine our efforts to develop a working vaccine, which will stop the pandemic and help to re-open the global economy.
It is not the first time Russia has faced international mistrust over its leadership in science when politics stand in the way of scientific breakthroughs and put public health at risk. During the polio outbreak in Japan in the 1950s Japanese mothers whose children were dying from polio, went to demonstrate against their own government, which banned imports of Soviet polio vaccine for political reasons. The protesters achieved their goal and the ban was lifted saving the lives of more than 20 million Japanese children.
Today politics again stand in the way of the Russian technology, which can save lives around the world. Russia is open to international cooperation in fighting this and future pandemics. In the words of a Soviet delegate at the international conference on polio vaccines in Washington in 1960 who said in response to questions from the audience about the vaccine’s safety that we in Russia “love our children and are concerned for their wellbeing as much as people in the United States, or any other part of the world are for their children”. After these words the Soviet delegation received a standing ovation from the audience and joint work on vaccines continued. The wellbeing and prosperity for future generations is what we need to think about now. All countries in the world need to leave politics behind and focus on finding the best solutions and technologies in order to protect lives and resume economic activity. Our fund has already secured manufacturing partnerships in 5 countries to jointly produce the Russian vaccine. Maybe at some point thanks to this partnership in fighting COVID-19 we can also review and abandon the politically motivated restrictions on international relations, which have become obsolete and represent an obstacle to coordinated efforts in dealing with global challenges.  
Kirill Dmitriev is chief executive officer of the Russian Direct Investment Fund, a sovereign wealth fund with $50 billion under management.    

REFERENCES AND LINKS 

The “Sputnik V” vaccine website
www.sputnikvaccine.com
Newsweek magazine opinion piece by Kirill Dmitriev, CEO of RDIF, “What Russia got right about the coronavirus - and what it can share with the world”.
https://www.newsweek.com/russia-got-right-coronavirus-covid-19-share-world-1517541

The Gamaleya Center COVID-19 Vaccine
Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04437875?term=Gamaleya&draw=2&rank=2
https://clinicaltrials.gov/ct2/show/NCT04436471?term=Gamaleya&draw=2&rank=3

The Gamaleya Center Ebola Vaccine
Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT03428347?term=Gamaleya&draw=2&rank=10
https://clinicaltrials.gov/ct2/show/NCT03072030?term=GamEvac&draw=2&rank=1
International patents:
International patent WO2016130047A1 Immunobiological drug and method for using same for inducing specific immunity against the Ebola virus - https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016130047
Russian Health Ministry registration certificates:
http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a52736b8-b1ac-408c-a2c1-3fb82c941267&t=
http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=a52736b8-b1ac-408c-a2c1-3fb82c941200&t=
http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3974b1cc-27ed-4032-94ec-8c897f2421d3&t=
Scientific publications:
Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Hum Vaccin Immunother. 2017 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5360131/
Dolzhikova IV, Tokarskaya EA, Dzharullaeva AS, et al. Virus-Vectored Ebola Vaccines. Acta Naturae. 2017. - http://actanaturae.ru/2075-8251/article/view/10364

Useful links:
Extract from Global Advisory Committee on Vaccine Safety meeting on 5-6 June 2019, published in the World Health Organization Weekly Epidemiological Record of 12 July 2019 https://www.who.int/vaccine_safety/committee/topics/ebola/Jul_2019/en/
Russian Foreign Ministry press release on the post-registration clinical trials of the Russian Ebola vaccine Gam Evac Combi in Guinea. https://www.mid.ru/en/main_en/-/asset_publisher/G51iJnfMMNKX/content/id/2838077
Russia and Rusal complete Ebola vaccinations in Guinea. Pharmaceutical Technology. https://www.pharmaceutical-technology.com/news/rusal-ebola-vaccinations-in-guinea/

GAMALEYA MERS VACCINE 

Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04130594?term=Gamaleya&draw=2&rank=4
https://clinicaltrials.gov/ct2/show/NCT04128059?term=Gamaleya&draw=2&rank=5
Russian Federation patent:
https://yandex.ru/patents/doc/RU2709659C1_20191219
Scientific publications:
Ozharovskaia TA, Zubkova OV, Dolzhikova IV, et al. Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein. Acta Naturae. 2019;11(1):38-47. - http://actanaturae.ru/2075-8251/article/view/10302/106

INFLUENZA VACCINE
Clinical trials:
https://clinicaltrials.gov/ct2/show/NCT04034290?term=Gamaleya&draw=2&rank=7
https://clinicaltrials.gov/ct2/show/NCT03651544?term=Gamaleya&draw=2&rank=9
Scientific publications:
Tutykhina I, Esmagambetov I, Bagaev A, et al. Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. Published 2018 Jan 29. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788337/
Tutykhina IL, Sedova ES, Gribova IY, et al. Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res. 2013;97(3):318-328. doi:10.1016/j.antiviral.2012.12.021 - https://pubmed.ncbi.nlm.nih.gov/23274786/
Tutykhina IL, Logunov DY, Shcherbinin DN, et al. Development of adenoviral vector-based mucosal vaccine against influenza. 2011. J Mol Med (Berl). - https://pubmed.ncbi.nlm.nih.gov/21104066/
International patents:
Patent WO2013129961A1 Recombinant trivalent vaccine against human influenza. - https://patentimages.storage.googleapis.com/b9/98/3c/5f0d7be2283729/EP2839840A1.pdf
 
GENERAL PUBLICATIONS ON ADENOVIRAL VECTOR-BASED VACCINES 

Future Prospects for the Development of Cost-Effective Adenovirus Vaccines. By Cyrielle Fougeroux and Peter J. Holst - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412272/
Repurposing Adenoviruses as Vectors for Vaccines. - https://thenativeantigencompany.com/repurposing-adenoviruses-as-vectors-for-vaccines/
Burmistrova DA, Tillib SV, Shcheblyakov DV, et al. Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis. PLoS One. 2016 - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150958
Shcherbinin DN, Esmagambetov IB, Noskov AN, et al. Protective Immune Response against Bacillus anthracis Induced by Intranasal Introduction of a Recombinant Adenovirus Expressing the Protective Antigen Fused to the Fc-fragment of IgG2a. Acta Naturae. 2014 - http://actanaturae.ru/2075-8251/article/view/10566/370Tutykhina I, Esmagambetov I, Bagaev A, et al. Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. Published 2018 Jan 29. - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788337/
Tutykhina IL, Sedova ES, Gribova IY, et al. Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection. Antiviral Res. 2013;97(3):318-328. doi:10.1016/j.antiviral.2012.12.021 - https://pubmed.ncbi.nlm.nih.gov/23274786/
Tutykhina IL, Logunov DY, Shcherbinin DN, et al. Development of adenoviral vector-based mucosal vaccine against influenza. 2011. J Mol Med (Berl). - https://pubmed.ncbi.nlm.nih.gov/21104066/
International patents:
Patent WO2013129961A1 Recombinant trivalent vaccine against human influenza. - https://patentimages.storage.googleapis.com/b9/98/3c/5f0d7be2283729/EP2839840A1.pdf
 
GENERAL PUBLICATIONS ON ADENOVIRAL VECTOR-BASED VACCINES 

Future Prospects for the Development of Cost-Effective Adenovirus Vaccines. By Cyrielle Fougeroux and Peter J. Holst - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412272/
Repurposing Adenoviruses as Vectors for Vaccines. - https://thenativeantigencompany.com/repurposing-adenoviruses-as-vectors-for-vaccines/
Burmistrova DA, Tillib SV, Shcheblyakov DV, et al. Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis. PLoS One. 2016 - https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0150958
Shcherbinin DN, Esmagambetov IB, Noskov AN, et al. Protective Immune Response against Bacillus anthracis Induced by Intranasal Introduction of a Recombinant Adenovirus Expressing the Protective Antigen Fused to the Fc-fragment of IgG2a. Acta Naturae. 2014 - http://actanaturae.ru/2075-8251/article/view/10566/370

hektore. u usporedbi hrvatske i rusije. hrvatska je twin turbo uređena u odnosu na rusiju.
potemkinova sela su i dalje potemkinova.
mađarska, rumunjska, bugarska, srbija, makedonija, albanija. čak i grčka su teške vukojebine prema hrvatskoj koja je vukojebina za jednu njemačku ili francusku.

veber wrote:hektore. u usporedbi hrvatske i rusije. hrvatska je twin turbo uređena u odnosu na rusiju.
potemkinova sela su i dalje potemkinova.
mađarska, rumunjska, bugarska, srbija, makedonija, albanija. čak i grčka su teške vukojebine prema hrvatskoj koja je vukojebina za jednu njemačku ili francusku.

Nije ni Njemačka bila nešto sriktana prije WW2... Američki gradovi su 70tih bili rupe... Da ne pričamo o promjenama u Kini od 1990te

A u Rusiji zadnjih godina to uređivanje ide i van Moskve, kažem po provinciji... Nikakva Potemkinova sela nego se lokalne vlasti natječu da zadovolje Federalni centar, ali i lokalno stanovništvo. Radi se sustavn redevelopment.


Jedan Kazan je fenomenalno sređen grad, isto i Tula, Rostov na Donu,...

Naši su se iznenadili za vrijeme svjetskog prvenstva

Hektorović wrote:

veber wrote:hektore. u usporedbi hrvatske i rusije. hrvatska je twin turbo uređena u odnosu na rusiju.
potemkinova sela su i dalje potemkinova.
mađarska, rumunjska, bugarska, srbija, makedonija, albanija. čak i grčka su teške vukojebine prema hrvatskoj koja je vukojebina za jednu njemačku ili francusku.

Nije ni Njemačka bila nešto sriktana prije WW2... Američki gradovi su 70tih bili rupe... Da ne pričamo o promjenama u Kini od 1990te

A u Rusiji zadnjih godina to uređivanje ide i van Moskve, kažem po provinciji... Nikakva Potemkinova sela nego se lokalne vlasti natječu da zadovolje Federalni centar, ali i lokalno stanovništvo. Radi se sustavn redevelopment.


Jedan Kazan je fenomenalno sređen grad, isto i Tula, Rostov na Donu,...

Naši su se iznenadili za vrijeme svjetskog prvenstva

dok se ne makneš od fasada. kao i bandič u zg.
jedini grad koji me ostavio paf je NY.
na potezu od 50 metara imaš ulični restoran za 3 dolara i fensi šmensi za 500 dolara, a ista klopa.

Veber je stručnjak za tende.

veber wrote:dok se ne makneš od fasada. kao i bandič u zg.
jedini grad koji me ostavio paf je NY.
na potezu od 50 metara imaš ulični restoran za 3 dolara i fensi šmensi za 500 dolara, a ista klopa.

Očajna infrastruktura, raspadajuće ceste.

Ima Amerika dobrih gradova, ali NY nije jedan od tih...

Maggie19 wrote:

Ringo10 wrote:

AssadNaPodmornici wrote:Tko će se cijepiti

Ugl ovo ruglo od korone je za par mjeseci valjda out forever.
Mrtvih ima jedva nešto više od jače gripe

Pa ako je Putin dao da mu se kćerka cijepi pa valjda je cjepivo pouzdano.

Jedan je frend na fejsu dobro napisao da ne vjeruje dok ne cijepi sina ;-D

Hijaaooooooooooooo 

Inače da malčice interesa pokažemo dobili bi ovo od Rusa prije nego Srbi ali eto mi volimo pedere i pedofile sa Zapada pa ništa od toga, brnjicu na usta i bit će vam dobro...

Brain32 wrote:Inače da malčice interesa pokažemo dobili bi ovo od Rusa prije nego Srbi ali eto mi volimo pedere i pedofile sa Zapada pa ništa od toga, brnjicu na usta i bit će vam dobro...

Srbi uopće nisu uključeni u ovu Rusku vakcinu... Nego Saudijska Arabija, Emirati, Filipini, Turska, Brazil i Indija.

Srbi je traže od "brata" Xi-ja

Molio bih ovoga maloumnog imbecila sa nickom VEBER da nas ovdje postedi svojih kretenskih drkotina ako vec nema sta pametnije da kaze

Bio sam u NY, centar na Manhatanu svaka cast, impresivno, ostalo je bez veze, gradusina ko gradusina

Hektorović wrote:

veber wrote:dok se ne makneš od fasada. kao i bandič u zg.
jedini grad koji me ostavio paf je NY.
na potezu od 50 metara imaš ulični restoran za 3 dolara i fensi šmensi za 500 dolara, a ista klopa.

Očajna infrastruktura, raspadajuće ceste.

Ima Amerika dobrih gradova, ali NY nije jedan od tih...

ne u smislu dobar.
ugođaj. s jedne strane ekipa žica par centi s druge se parkiraju mercedesi.
grad sam po sebi.
dinamičan.

Ringo10 wrote:Molio bih ovoga maloumnog imbecila sa nickom VEBER da nas ovdje postedi svojih kretenskih  drkotina ako vec nema sta pametnije da kaze

i tebe peče?

Ringo10 wrote:Bio sam u NY, centar na Manhatanu svaka cast, impresivno, ostalo je bez veze, gradusina ko gradusina

Oko Times Squarea je danas pristojno, prije 25 godina je bila katastrofa



Ali grad ima ogromne probleme sa održavanjem infrastrukture.

Dosadan si...nikad svoju smrdljivu nosinu nisi promolio u jedan pedalj Rusije niti imas pojma o bilo cemu vezano za tu Zemlju ali sebi dajes za pravo da seres o necemu o cemu nemas blage veze

Znanstvenici o ruskom cjepivu: "Njihov potez je bezobziran"
prije 2 sata


Foto: EPA
RUSKA najava odobrenja za cjepivo protiv koronavirusa nakon manje od dva mjeseca kliničkih ispitivanja na ljudima izazvala je uzbunu među stručnjacima za javno zdravlje koji kažu da je teško vjerovati cjepivu za koje nisu objavljeni svi podaci iz tih ispitivanja.
Odlučna da bude prva u svjetskoj utrci u razvoju cjepiva protiv pandemijske bolesti covid-19, Rusija tek treba provesti kliničko ispitivanje širokih razmjera koje će rezultirati podacima o tome djeluje li - a to je, prema imunolozima i stručnjacima za zarazne bolesti, "lakomisleni" potez.
"Rusija zapravo provodi eksperiment na razini velike populacije", kaže Ayfer Ali, specijalistica za ispitivanja lijekova u Warwick Business School u Britaniji.
Upozorava na teške nuspojave
Ona kaže da takvo munjevito odobravanje može značiti da se moguće negativne nuspojave cjepiva neće otkriti. A one, iako vjerojatno rijetke, mogle bi biti teške, upozorava ona.
Ruski predsjednik Vladimir Putin objavio je da je cjepivo koje je razvio moskovski institut Gamaleja sigurno i da je dano jednoj od njegovih kćeri.
Francois Balloux, stručnjak genetskog instituta pri University College London, kaže da je to "lakomislena i blesava odluka".
"Masovno cijepljenje s neprimjereno testiranim cjepivom neetično je", kaže on. "Bilo koji problem s ruskim programom cijepljenja bio bi poguban i s negativnim učincima na zdravlje, a i zbog toga što bi odgodio prihvaćanje cjepiva u populaciji.”
Kažu da bi šteta mogla biti veća od sadašnjih problema
Njegove riječi potvrđuje i Danny Altmann, profesor imunologije na Imperial College London, koji kaže da bi kolateralna šteta primjene cjepiva za koje se ne zna je li sigurno i učinkovito bilo "nepremostivo povećanje naših sadašnjih problema".
U ovom trenutku desetak proizvođača lijekova širom svijeta, koji razvijaju cjepivo, provodi ispitivanja mogućih cjepiva na velikom uzorku stanovništva, a svako ispitivanje uključuje desetke tisuća dobrovoljaca.
Nekoliko njih koji su najviše odmaknuli poput Moderne, Pfizera i AstraZenece nadaju se da će do kraja godine znati jesu li njihova cjepiva sigurna.
Svi će objaviti rezultate ispitivanja i podatke o sigurnosti cjepiva i podnijet ih nadležnim tijelima u SAD-u, Europi i drugdje na provjeru.
Rusko je ministarstvo zdravlja takvo odobrenje izdalo prije takvih ispitivanja koja obično označavaju treću fazu ispitivanja i uključuju tisuće ispitanika. Takva ispitivanja smatraju se neophodnim preduvjetom ishođenja odobrenja za stavljanje u promet cjepiva.
"Ruski potez je bezobziran"
Peter Kremsner, stručnjak njemačke sveučilišne bolnice u Tübingenu, koji radi na kliničkom ispitivanju cjepiva CureVac, kaže da je ruski potez bezobziran.
"Normalno trebate veliki broj ljudi testirati prije odobrenja cjepiva", kaže on. "Mislim da je bezobzirno to učiniti ako nisu testirani mnogi ljudi."
Stručnjaci ističu da izostanak objavljivanja podataka o ruskom cjepivu uključujući kako je napravljeno i detalje o sigurnosti, imunom odgovoru i može li spriječiti infekciju covid-19 ostavlja u mraku znanstvenike, zdravstvene vlasti i javnost.
"Nemoguće je znati je li rusko cjepivo učinkovito bez podnošenja znanstvenih podataka na analizu", kaže Keith Neal, stručnjak za epidemiologiju zaraznih bolesti na britanskom sveučilištu Nottingham.

https://www.index.hr/vijesti/clanak/znanstvenici-zabrinuti-zbog-ruskog-cjepiva-provode-eksperiment-na-siroj-populaciji/2204451.aspx